Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug336 | Azithromycin / Ribaroxaban / Paracetamol Wiki | 1.00 |
drug3790 | glenzocimab Wiki | 1.00 |
drug2448 | Placebo Wiki | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
D013577 | Syndrome NIH | 0.10 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
D055371 | Acute Lung Injury NIH | 0.08 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
The present study is designed for patients with mild COVID-19 phase, to demonstrate if there is a modification in the clinical evolution greater than or equal to 25% in their symptoms, implemented in two groups of patients under an early intervention treatment, a group ( A) will receive Azithromycin / Ivermectin / Ribaroxaban / Paracetamol and another group (B) will receive Azithromycin / Ribaroxaban / Paracetamol followed for 14 days followed by video call
Description: Assuming 25% efficacy in modifying the clinical course (Symptoms of fever, cough, headache, myalgia, odynophagia, anosmia, rhinorrhea, arthralgia, chest pain, dyspnea, conjunctivitis) of patients diagnosed with COVID-19 under treatment comparative of early intervention for 14 days followed by video call, with a power of 90%, a type I error rate of 1% and a loss to follow-up of 20%; We calculated a total of 62 patients with COVID-19, that is, 31 cases in group A with Azithromycin / Ivermectin / Ribaroxaban / Paracetamol treatment and 31 in group B with Azithromycin / Ribaroxaban / Paracetamol treatment would be necessary for the analysis. Statistical differences will be evaluated using the Mann-Whitney U test. The analyzes will be performed in SPSS version 21
Measure: Estimate clinical symptoms by days of follow-up in patients with COVID-19 under treatment with Azithromycin/Ivermectin/Ribaroxaban/Paracetamol vs. Azithromycin/Ribaroxaban/Paracetamol followed by video call for 14 days from U.M.F 13 and U.M.F 20 Time: 14 daysDescription: Assuming a 25% efficacy in modifying the clinical course (adverse reactions) of patients diagnosed with COVID-19 under a comparative early intervention treatment for 14 days followed by video call, with a power of 90%, an error rate type I of 1% and loss to follow-up of 20%; We calculated a total of 62 patients with COVID-19, that is, 31 cases in group A with Azithromycin / Ivermectin / Ribaroxaban / Paracetamol treatment and 31 in group B with Azithromycin / Ribaroxaban / Paracetamol treatment would be necessary for the analysis. Statistical differences will be evaluated using the Mann-Whitney U test. The analyzes will be performed in SPSS version 21
Measure: To assess adverse drug reactions by days of follow-up in patients with COVID-19 under treatment with Azithromycin/Ivermectin/Ribaroxaban /Paracetamol vs. Azithromycin /Ribaroxaban/Paracetamol followed by video call for 14 days from U.M.F 13 and U.M.F 20 Time: 14 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports